CD34 and acute myeloid leukemia: They have clinical impact potential in high-risk MDS as it may both prevent disease progression/immune evasion by reducing the numbers of CD123+ MDSC (Edwards et al., 2010; Gustafson et al., 2015; Uhel et al., 2019; Dysthe and Parihar, 2020; Khan et al., 2020; Domagala et al., 2021) and delay the development of secondary AML by T-cell mediated destruction of CD123+CD34+ blast cells.